Novo Nordisk U.S. News & Media Hub
Welcome to Novo Nordisk's U.S. news and media hub. Here you can access our news releases, social media accounts, media contacts, sign up for email alerts, and more.
www.novonordisk-us.comHere are the latest Novo Nordisk news highlights from reputable sources:
-
Novo Nordisk has been in focus for updates around Wegovy access and pricing, including partnerships and regulatory developments aimed at expanding patient access while addressing counterfeit semaglutide products. These topics have been prominent in late 2025 and early 2026 coverage. [cite ]
-
Public reporting in late 2025 noted pricing adjustments for Wegovy and Ozempic in some markets, along with workforce reductions at the company and executive leadership changes. These moves reflect ongoing pricing pressures and strategic realignments in response to competitive dynamics. [cite ]
-
Clinical and pipeline news around semaglutide-related therapies continued to surface in 2025, including mixed results from related trials and continued emphasis on diabetes and obesity treatment leadership. Investors and patients alike have been watching for updates on efficacy, safety, and long-term outcomes. [cite ]
-
Novo Nordisk maintains an active Newsroom and U.S. media hub where they publish press releases and updates; for the most current items, check the official Novo Nordisk Newsroom and U.S. media pages. [cite ][cite ]
If you’d like, I can pull the very latest headlines from specific outlets (e.g., official Novo Nordisk newsroom, major business outlets, or a regional market) and summarize them with direct quotes. I can also set up a quick briefing card with key metrics (FDA activity, pricing changes, major partnerships) and provide sources after each item.